[go: up one dir, main page]

WO2007030580A2 - Agents neuroprotecteurs - Google Patents

Agents neuroprotecteurs Download PDF

Info

Publication number
WO2007030580A2
WO2007030580A2 PCT/US2006/034796 US2006034796W WO2007030580A2 WO 2007030580 A2 WO2007030580 A2 WO 2007030580A2 US 2006034796 W US2006034796 W US 2006034796W WO 2007030580 A2 WO2007030580 A2 WO 2007030580A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
excitotoxic
preconditioning
event
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034796
Other languages
English (en)
Other versions
WO2007030580A3 (fr
Inventor
Mary Stenzel-Poore
Susan Stevens
Roger Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of WO2007030580A2 publication Critical patent/WO2007030580A2/fr
Publication of WO2007030580A3 publication Critical patent/WO2007030580A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This disclosure relates to the field of neurology. More specifically, the present disclosure relates to the prevention and/or treatment of cellular and organ damage due to excitotoxic injury, ischemia and/or hypoxia.
  • Ischemic tolerance in the brain in which one or more brief ischemic insults increase resistance to subsequent injurious ischemia — is a powerful adaptive defense that involves an endogenous program of neuroprotection (Nandagopal et al, J. Phartn. Exp. Tlier. 297:474-478, 2001; Chen et al., J. Cereb. Blood Flow Metab. 16:566-577, 1996; and reviewed in Dirnagl eC al., Trends Neruosci. 26:248-254, 2003).
  • This neuroprotective program sets into motion a complex cascade of signaling events, leading to synthesis of new proteins, that ultimately re-programs the cellular response to subsequent injury.
  • Tolerance to ischemic brain injury can be induced by several distinct preconditioning stimuli including non-injurious ischemia, cortical spreading depression, brief episodes of seizure, exposure to anesthetic inhalants, and low doses of endotoxin (lipopolysaccharide, LPS) (Simon et al, Neurosci. Lett. 163:135-137, 1993; Chen and Simon, Neurology, 48:306-311, 1997; Kitagawa et al, Brain Res. 528:21-24, 1990; Kobayashi e? ⁇ /. , /. Cereb. Blood Flow Metab.
  • endotoxin lipopolysaccharide, LPS
  • LPS given in small doses, confers profound neuroprotection against subsequent stroke.
  • Certain features of LPS-induced neuroprotection make it an extremely promising target for stroke therapy: 1) systemic delivei ⁇ of LPS induces robust neuroprotection, thus blood-brain barrier issues are not a concern; 2) neuroprotection occurs rapidly — within one day of administration and perhaps sooner; and 3) neuroprotection lasts at least one week following LPS treatment.
  • LPS is poorly tolerated by human and animal subjects.
  • the present disclosure provides improved compositions and methods for protecting subjects against the adverse effects of stroke and other hypoxic and/or excitotoxic injuries.
  • the present disclosure relates to methods and compositions for protecting cells against cytotoxic insult.
  • the methods disclosed herein are applicable to the protection of neural as well as non-neural cells, and are relevant for the prevention of adverse outcomes due to diverse medical conditions, including epilepsy, traumatic brain injury, in utero hypoxia, ischemic events (including stroke) and Alzheimer's disease, as well as surgical and non-surgical trauma.
  • the methods involve systemically administering one or more compositions (medicaments) that elicit a protective effect to a subject.
  • at least one of the compositions is administered prior to the excitotoxic and/or hypoxic event, or prior to one or more events in a series of events or during the occurrence of an ongoing or progressive process.
  • a second composition is administered following the onset of an excitotoxic and/or hypoxic event.
  • the disclosure relates to methods for the treatment (e.g., prophylactic and/or therapeutic treatment) of cellular injury and death due to cytotoxic insults, such as excitotoxic, ischemic and/or hypoxic events.
  • FIG. 1 is a bar graphs illustrating neuroprotection following in vitro treatment with an exemplary CpG oligonucleotide. Values are group means +/- SEM; *P ⁇ 0.05.
  • FIG. 2 is a bar graph illustrating neuroprotection in vivo following treatment of mice with an exemplary CpG oligonucleotide.
  • CpG treatment was given 72 hrs prior to induced stroke. Values are group means +/- SEM; * p ⁇ 0.05, **p ⁇ 0.001.
  • nucleic and amino acid sequences listed herein and/or in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
  • SEQ ID NO: 1 (5'-tccatgacgttcctgacgtt-3') is an exemplary oligonucleotide that binds to and activates mouse TLR9.
  • SEQ ID NO:2 (S'-gggggacgatcgtcgggggg- ⁇ ') is an exemplary human Class A CpG oligonucleotide.
  • SEQ ID NO:3 (5'-tcgtcgtttttgtcgttttgtcgtcgttcgttt-3') is an exemplary human Class B CpG oligonucleotide.
  • SEQ ID NO:4 (5'-tcgtcgtcgttcgttcgaacgacgttgat-3') is an exemplary human Class C CpG oligonucleotide.
  • SEQ ID NO:5 (5'-tgactgtgaacgttcgagatga-3') is an exemplary human Class B CpG oligonucleotide.
  • SEQ ID NO:6 EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT
  • SEQ ID NO:7 CIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT
  • SEQ ID NO: 8 (EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKT) is an exemplary C-terminal deletion derivative of the PcTx peptide.
  • SEQ ID NO:9 (EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVC) is an exemplary N- terminal deletion derivative of the PcTx peptide.
  • SEQ ID NO: 10 (CIPKWKGCVNRHGDCCEGLECWKRRRSFEVC) is an exemplary PcTx peptide with both N-terminal and C-terminal deletions.
  • the present disclosure concerns methods for protecting cells in vivo, in the context of a living multicellular organism, from the adverse effects of cytotoxic insults, such as excitotoxic, ischemic and/or hypoxic events. More specifically, methods disclosed herein involve preconditioning cells to increase tolerance to subsequent excitotoxic, ischemic and/or hypoxic events.
  • the present disclosure provides novel methods, based on the observation that oligonucleotides including an unmethylated CpG motif are cytoprotective when used in a preconditioning regimen, for protecting cells against excitotoxic injury, ischemia and hypoxia.
  • CpG oligonucleotides and/or other preconditioning agents induces cellular and metabolic changes by modifying the genomic response program, which results in resistance to subsequent damage that would otherwise result from excessive electrochemical activity and/or oxygen deprivation.
  • the preconditioning regimen is combined with an acute therapeutic regimen.
  • the therapeutic aspect of the treatment regimen involves administering an inhibitor of an acid sensing ion channel (ASIC), such as the Tarantula toxin psalmotoxin 1 (PcTx).
  • ASIC acid sensing ion channel
  • the composition is administered after the onset of an excitotoxic and/or hypoxic event.
  • a composition such as PcTx can be administered in the period following an acute excitotoxic and/or hypoxic event.
  • one aspect of the disclosure concerns methods of protecting a cell (or population of cells, or a tissue, organ or organism) against cytotoxic insult, including excitotoxic injury, ischemia, hypoxia or a combination of thereof.
  • the methods disclosed herein are applicable to different cell types susceptible to excitotoxic, ischemic and/or hypoxic injury, which are amenable to preconditioning.
  • neural cells including, e.g., hippocampal neurons and cortical neurons
  • muscle cells including cardiac, smooth and striated muscle cells
  • hepatic cells including renal cells and endothelial cells
  • renal cells and endothelial cells can be protected against excitotoxic injury, ischemia and/or hypoxia using the methods disclosed herein.
  • certain cells of the immune system including macrophages and microglia are amenable to preconditioning.
  • the disclosed methods can be utilized to protect cells from cytotoxic insult, for example, arising from excitotoxic, ischemic and/or hypoxic events. That is, the methods are useful for protecting cells from a broad range of events and occurrences that include an excitotoxic, ischemic or hypoxic component, or a combination thereof.
  • Excitotoxic injury results from excessive stimulation of cells (typically neural cells in the CNS) by certain neurotransmitter (e.g., glutamate) receptors.
  • excitotoxic injury can be a result of a condition that causes excessive chemical or electrical activity in the brain or it can be a result of conditions that cause a decrease in inhibitory or regulatory functions of the brain.
  • Excitotoxic injury in the brain is associated with a variety of conditions with disparate etiologies and symptoms, including epilepsy, traumatic brain injury and Alzheimer's disease.
  • Hypoxia in the central nervous system (CNS) can be associated with ischemic events (such as cerebrovascular ischemia, or stroke, myocardial ischemia due to narrowing or blockage of the vessels of the heart, iatrogenic ischemia, due to surgical procedures, and the like).
  • hypoxia can occur in utero due to conditions such as inadequate placental function (for example, due to abrupio placentae), preeclamptic toxicity, prolapse of the umbilical cord, or complications from anesthetic administration.
  • Ischemic events outside the CNS can also result in injury to tissues and organs, including kidney, liver and muscle. Such injury can be the result of vascular disease or injury, as well as a complication of surgical procedures (e.g., cardiovascular surgery). Additionally, injury by some hypoxic events (such as strokes) involves an excitotoxic component as well as a hypoxic component and are, in some but not all cases related to ischemic events. Thus, it will be appreciated that these terms can be extensively overlapping, but are not necessarily coextensive in every condition that is amenable to preconditioning. For simplicity of reference, in the context of this disclosure, the term "cytotoxic insult” is used to refer to any of these conditions, separately or in any combination. The methods disclosed herein are useful for preventing cellular damage in any (and/or all) of these conditions.
  • the methods can involve selecting a subject at risk for one or more of an excitotoxic, ischemic or hypoxic event.
  • risk is indicated by a variety of medical as well as non-medical indicators, as would be recognized by one of ordinary skill in the art.
  • various cardiovascular signs and symptoms such as atrial fibrillation, angina pectoris, hypertension, transient ischemic attacks and prior stroke, are all indicators of risk that can be used to select a subject for administration of preconditioning agent according to the methods disclosed herein.
  • surgical procedures especially those specifically involving the cardiovascular system, such as endarterectomy, pulmonary bypass and coronary artery bypass surgeries, are indicators of risk that can be used to select a subject for administration of a preconditioning agent.
  • non-medical indicators of risk can include an excitotoxic or hypoxic component.
  • traumatic brain injury (regardless of its cause) frequently involves an excitotoxic (and can also include a hypoxic) component.
  • participation in activities that increase the risk of traumatic brain injury are indicators that can be used to select a subject for administration of a preconditioning agent (such as a CpG oligonucleotide).
  • a preconditioning agent such as a CpG oligonucleotide
  • activities include, for example, motorcycle riding, motor vehicle racing, skiing, contact sports (such as, football, hockey, rugby, soccer, lacrosse, martial arts, boxing and wrestling), and the like.
  • the methods involve systemically administering a composition including an oligonucleotide (or a mixture of oligonucleotides) comprising an unmethylated CpG motif.
  • a composition including a CpG oligonucleotide is administered to a subject (such as a human subject) at risk for a cytotoxic insult, such as an excitotoxic, ischemic and/or hypoxic event.
  • the composition containing the CpG oligonucleotide(s) is a pharmaceutical composition or medicament, formulated for administration to a subject.
  • Such compositions commonly include a pharmaceutical carrier or excipient.
  • the composition is formulated based on the intended route of administration.
  • Suitable routes of administration include intranasal, oral, transdermal, subcutaneous, intrathecal, intravenous and intraperitoneal routes, and appropriate pharmaceutical carriers for these administration routes are well known in the art.
  • a CpG oligonucleotide in the preparation of a medicament for the prophylactic treatment of an excitotoxic injury, ischemia or hypoxia (or an increased risk thereof) is a feature of this disclosure.
  • the composition is typically administered prior to an event or activity associated with (e.g. , that increases the risk of) excitotoxic injury, ischemia and/or hypoxia.
  • an event or activity associated with e.g. , that increases the risk of
  • at least one dose of the composition is admim'stered at least 10 hours prior to the event or activity, in order to better realize the preconditioning effect of administration.
  • the composition is administered at least 24 hours before the event or activity.
  • the protective effects of a single administration of a CpG composition can last for greater than one week (e.g., up to about 10 days, or more).
  • the composition is given prior to the commencement of the event, such as about 10 hours, or about 12 hours, or about 24 hours prior to the event or activity, and can be given up to about 1 week prior to the event.
  • multiple doses of the composition are administered prior to the commencement of the event (e.g., surgery).
  • two, or three, or more doses can be administered on separate occasions preceding the event.
  • a first dose is typically given between 8 and 10 days, at seven days, at six days, at five days, at four days, at three days, at two days, or at 1 day prior to the event.
  • One or more subsequent administrations of the compositions can be made at any subsequent time point, such as at seven days, at six days, at five days, at four days, at three days, at two days, at 24 hours or at 12 hours prior to the event.
  • a recurrent event such as repeated engagement in a contact sport
  • multiple administrations are given, the ultimate dose (that is, the most recent dose prior to the event) being given prior (such as, at least 10 hours, or up to about 1 week, prior) to the event or activity.
  • the ultimate dose that is, the most recent dose prior to the event
  • prior such as, at least 10 hours, or up to about 1 week, prior
  • multiple administrations are given, for example on a predetermined schedule, such as at weekly intervals.
  • the individual treatment regimen can be customized to the particular subject event or activity, such that the protective effects of the preconditioning dose of the CpG oligonucleotide are optimized under the particular circumstances for the particular subject.
  • the dose of the composition including the CpG oligonucleotide administered is a preconditioning dose. That is, a dose of the composition is administered that is sufficient to induce cellular changes (for example, in the genomic response) that protect the cell against injury resulting from a subsequent cytotoxic insult, such as an excitotoxic, ischemic or hypoxic event. Methods for detecting such genomic changes are described hereinbelow, e.g., in Example 2.
  • a preconditioning dose (for example, in a human) includes at least 0.005 mg/kg, such as about 0.01 mg/kg of the oligonucleotide. Usually the dose contains no more than about 0.8 mg/kg of the oligonucleotide.
  • a preconditioning dose can include between 0.01 mg/kg and 0.25 mg/kg of a CpG oligonucleotide, such as between 0.05 mg/kg and 0.2 mg/kg of the CpG oligonucleotide.
  • Certain exemplary doses include about 0.07, about 0.08, about 0.09, about 0.10, about 0.12 or about 0.15 mg/kg of a CpG oligonucleotide.
  • the oligonucleotide(s) binds to and activates a Toll-like receptor 9 (TLR9). Binding of TLR9 by a suitable CpG oligonucleotide ligand results in the activation of intracellular signaling pathways that modify the genetic program in cells expressing the receptor. These modifications in the genomic response include an increase in the production of certain cytoprotective cytokines.
  • binding of a CpG oligonucleotide to TLR9 on the cell surface of certain immune cells induces production of transforming growth factor-beta (TGF ⁇ ), tumor necrosis factor-alpha (TNF ⁇ ;) and type I interferons, such as interferon-beta (IFNjS).
  • TGF ⁇ transforming growth factor-beta
  • TNF ⁇ tumor necrosis factor-alpha
  • IFNjS type I interferons
  • representative methods disclosed herein involve administering a CpG oligonucleotide capable of inducing production of one or more cytoprotective cytokines, such as TGFft TNF ⁇ , and IFN/3.
  • CpG oligonucleotides have been described, and are known to bind to TLR9 and induce cellular signaling pathways. Any of these oligonucleotides can be used in the context of composition for preconditioning a cell against excitotoxic or hypoxic injury.
  • the oligonucleotide can be modified by the inclusion of one or more phosphorothioate modified nucleotides. Exemplary oligonucleotide sequences suitable for use in mouse (SEQ ID NO:1) and human (SEQ ID NOs:2-5).
  • One aspect of this disclosure concerns methods for reducing cytotoxic injury due to excitotoxic, ischemic and/or hypoxic events by administering a preconditioning composition in combination with a second composition, which is administered concurrently with or after the onset of the excitotoxic and/or hypoxic event (for example, during or soon following the event).
  • a preconditioning regimen in combination with acute administration of a second composition, such as an acid sensing ion channel (ASIC) inhibitor.
  • ASIC acid sensing ion channel
  • the preconditioning and acute treatments provide enhanced protection as compared to no treatment or to either treatment alone.
  • the method for protecting a cell involves administering an agent that binds to and activates a Toll-like receptor (as disclosed herein) and administering a composition that includes an ASIC inhibitor.
  • the agent that binds to and activates a Toll-like receptor can be a CpG oligonucleotide or imiquimod.
  • the ASIC inhibitor can be Tarantula psalmotoxin 1 (PcTx) or a peptide that is structurally related to PcTx.
  • the ASIC inhibitor can by systemically or locally administered, for example, by intranasal, transdermal, oral, intrathecal, intravenous and/or intraperitoneal delivery in one or more doses.
  • the disclosure provides for the use of an ASIC inhibitor in the preparation of a pharmaceutical composition or medicament that enhances or increases the protective effect (e.g., against excitotoxic, ischemic and/or hypoxic injury) of treating a subject with a preconditioning regiment including an agent that binds to and activates a Toll-like receptor.
  • a preconditioning regiment including an agent that binds to and activates a Toll-like receptor.
  • TLR Toll-like receptor
  • CNS central nervous system
  • the peripheral or CNS cells that express TLRs can be non-neural cells.
  • the non-neural cells can be immune cells, such as B cells, dendritic cells, macrophages or microglia.
  • Agents that bind to various TLRs, including TLR2, TLR4, TLR7 and TLR9, among others, are useful in the methods disclosed herein.
  • the agent is an unmethylated CpG oligonucleotide that binds to and activates TLR9.
  • the agent is imiquimod or another agent that binds to and activates TLR7.
  • the agent is MALP-2, which binds to and activates TLR2 or a nontoxic analog LPS, which binds to and activates TLR4.
  • such agents are administered in combination with an ASIC inhibitor, such as PcTx.
  • Excitotoxic brain injury can be the result of a variety of disparate events.
  • the disclosed methods are suitable for protecting cells from injury or death due to epilepsy, traumatic brain injury and Alzheimer's disease, as well as stroke.
  • the agent binds to a TLR and induces cellular changes (for example, in the genomic program), such as inducing production of one or more neuroprotective cytokines, such as TGF/3, TNF ⁇ , and IFN/3.
  • the agent that binds to the TLR is administered prior to the excitotoxic event.
  • the agent can be administered to a subject identified as being at risk for an excitotoxic brain injury.
  • the agent is administered to a subject prior to a surgical procedure, such as a surgical procedure involving the CNS or cardiovascular system.
  • a surgical procedure such as a surgical procedure involving the CNS or cardiovascular system.
  • such methods can be employed to protect a subject from excitotoxic brain injury resulting from surgical procedures involving arterial bypass, which are associated with an increased risk of excitotoxic brain injury, such as endarterectomy, pulmonary bypass and coronary artery bypass surgeries.
  • Surgical interventions are typically non-recurring events; thus, the agent can be administered prior to the event in a single dose delivered prior to the start of the event.
  • the agent is usually administered at least about 10 hours prior to the event (for example, surgery), and can be administered up to about 1 week prior to the event.
  • more than one doses of the agent are administered prior to the event.
  • one or more doses of a second composition containing an ASIC inhibitor can be administered during and/or following the procedure or event.
  • TLR Toll-like receptor
  • the TLR is expressed by a cell other than a cell of the central nervous system.
  • the non- neural cell can be a muscle cell (including a skeletal, smooth or cardiac muscle cell), a kidney cell a liver cell, an endothelial cell or a cell of the immune system (such as a macrophage or microglial cell).
  • the ischemic event is associated with a surgical procedure, such as coronary artery bypass surgery.
  • the agent is administered prior to the onset of ischemia.
  • the agent binds to TLR9. In another embodiment, the agent binds to TLR7 (and/or TLR8). In yet other embodiments, the agents bind to TLR2 or TLR4. Exemplary agents include CpG oligonucleotides, imiquimod, MALP-2 and nontoxic LPS analogs.
  • the agent(s) that bind to a TLR are administered in combination with an agent that inhibits an ASIC.
  • the ASIC inhibitor is administered following onset of ischemia. In one particular example, the ASIC inhibitor is PcTx.
  • excitotoxic injury or "excitotoxic brain injury” refers to injury (including death), of neural cells, particularly neural cells of the brain, due to excessive stimulation of cell- surface receptors. Most commonly, excitotoxic injury is mediated through glutamate receptors, for example, by overactivation of N-methyl-d-aspartate (NMDA)-type glutamate receptors, resulting in excessive Ca 2+ influx through the receptor's associated ion channel. Excitotoxic injury is believed to play a role in diverse conditions, including epilepsy, traumatic injury, and Alzheimer's disease.
  • NMDA N-methyl-d-aspartate
  • hypoxia refers to a lack of oxygen.
  • hypoxia refers to an insufficiency of oxygen at a cellular, tissue or organismal level. Hypoxia can be caused by, for example, the reduction in partial pressure of oxygen (in the blood or in a tissue), inadequate oxygen transport (for example, due to a failure of oxygenated blood to reach a target tissue or cell), or the inability of the tissues to use oxygen.
  • the te ⁇ n "infarct” refers to cell or tissue death due to a localized lack of oxygen (hypoxia).
  • hypoxia is the result of "ischemia," the reduction in oxygenated blood flow to a target tissue or organ.
  • An "ischemic event” is an event or occurrence that results in decreased blood flow to a cell, collection or group of cells, tissue, or organ. Ischemic events include vasoconstriction, thrombosis and embolism, resulting in reduced blood flow to a tissue or organ.
  • the term "stroke” refers to an interruption of the blood supply to any part of the brain.
  • a stroke can be due to an ischemic event (for example, occlusion of a blood vessel due to a thrombus or an embolism) or hemorrhage (for example, of a cerebral blood vessel).
  • a subject is at "risk for a cytotoxic insult” or at "risk for an excitotoxic, ischemic or hypoxic event” if there is an increased probability that the subject will undergo a excitotoxic, ischemic or hypoxic event relative to the general population.
  • risk is a statistical concept based on empirical and/or actuarial data.
  • risk can be correlated with one or more indicators, such as symptoms, signs, characteristics, properties, occurrences, events or undertakings, of a subject.
  • indicators include but are not limited to high blood pressure (hypertension), atrial fibrillation, transient ischemic events, prior stroke, diabetes, high cholesterol, angina pectoris, and heart disease.
  • risk indicators for hypoxic events include surgery, especially cardiovascular surgeries, such as endarterectomy, pulmonary bypass surgery or coronary artery bypass surgery. Additional risk factors or indicators include non-medical activities, such as motorcycle riding, contact sports and combat. Other risk factors are discussed herein, and yet more can be recognized by those of ordinary skill.
  • the term "protect" with respect to a excitotoxic or hypoxic event refers to the ability of composition or treatment regimen to prevent, reduce in severity, or otherwise lessen the effects of an excitotoxic or hypoxic event at a cellular, tissue or organismal level.
  • Methods for measuring severity of effects of an excitotoxic or hypoxic event include neurological, including behavioral, indicia (e.g., ascertainable via neurological examination of a subject) as well as by evaluation of cellular and metabolic parameters, for example, by Computed Axial Tomography (CT scan, CAT scan); Magnetic Resonance Imaging (MRI scan, MR scan); Carotid Ultrasound, including Transcranial Doppler (TCD); Cerebral Angiography: (Cerebral arteriogram, Digital subtraction angiography [DSA]); Computed Tomographic Angiography: (CT-angiography, CT-A, CTA); Magnetic Resonance Angiography (MRA) and/or other diagnostic procedures known to those of ordinary skill in the art.
  • CT scan Computed Axial Tomography
  • MRI scan Magnetic Resonance Imaging
  • MR scan Magnetic Resonance Imaging
  • Carotid Ultrasound including Transcranial Doppler
  • TCD Transcranial Doppler
  • a "CpG oligonucleotide” or “CpG ODN” is a nucleotide molecule, typically between about 12 and 30 nucleotides in length and including at least one unmethylated cytosine-guanosine dinucleotide. Generally, the unmethylated CpG dinucleotide is located at the interior of the nucleotide sequence rather than at an end. Unmethylated CpG dinucleotides are found throughout various genomes, including those of many bacteria and viruses. However, in the context of this disclosure, the CpG oligonucleotide is a synthetic (or isolated) nucleotide sequence. In some cases, the CpG oligonucleotide includes one or more nucleotide with a phosphorothioate modified backbone to increase stability of the CpG oligonucleotide in vivo.
  • a "Toll-like receptor” or “TLR” is a type I transmembrane protein which acts as a pattern recognition receptor (PRR). Toll-like receptors have been shown to play a role in innate immunity, for example, by recognizing conserved microbial structures or Pathogen-Associated Molecular Patterns (PAMP). More than a dozen TLRs are known, and the nucleic acids that encode them have been described. For example, nucleic acid sequences that encode human TLRs can be found, e.g., in GENBANK®: Accession nos.
  • TLRl U88540 (TLRl); U88878 (TLR2); U88879 (TLR3); U88880 (TLR4) AB060695 (TLR5); AB020807 (TLR6); AF245702 (TLR7); AF245703 (TLR8); AF245704, and splice variants AF259262 and AF259263 (TLR9); and AF296673 (TLRlO), among others, the sequences of which are well known. Naturally occurring and artificial ligands of several TLRs have been characterized.
  • peptidoglycan fragments bind to TLR4; dsRNA (a viral product) binds to TLR3; LPS (a component of bacterial cell walls) binds to TLR4; bacterial flagellin binds to TLR5; single stranded RNA (such as viral RNA) binds to TLR7 and TLR8; and unmethylated CpG motifs (such as those found in the genome of bacteria and viruses) bind to TLR9.
  • a ligand is said to "activate" a receptor if the ligand binds to the receptor, and such binding results in the initiation of one or more signaling events, such as translocation or phosphorylation of the receptor and/or other signaling molecules.
  • systemic and “systemically” are used in reference to administration/administering of a composition to indicate that administration results in the composition contacting cells and/or tissues at one or more sites at a distance to the site of administration, including cells and/or tissues of an organ or body part that is not the organ or body part into which the composition is directly administered.
  • systemic administration involves introducing the composition directly or indirectly into the circulatory system of the organism.
  • intravenous administration is one method of systemic administration of a composition.
  • a composition can be systemically administered by introducing the composition into a site that indirectly results in the composition being introduced into (either by diffusion or an active transport process) the circulatory system of the organism.
  • intranasal, oral, transdermal, subcutaneous, intramuscular, intrathecal and intraperitoneal routes can all be systemic administration of the composition.
  • systemic is used to distinguish the administration route from methods that result in a composition being retained in close proximity (for example, within the same tissue or organ) to the site of introduction.
  • a "subject” is a living multi-cellular vertebrate organism, a category that includes both human and veterinary subjects, including human and non-human mammals. In a clinical setting with respect to preconditioning against excito toxic injury and/or hypoxia, a subject is usually a human subject, although veterinary subjects are also contemplated.
  • a "neural cell” is any cell in a lineage that originates with a neural stem cell and includes a mature neuron.
  • the term neural cell includes neurons (nerve cells) as well as their progenitors regardless of their stage of differentiation. In the context of an adult brain, neural cells are predominantly differentiated neurons.
  • a "non-neural cell” is a cell of a lineage other than a neural cell lineage, that is a lineage that does not culminate in the differentiation of a mature neuron.
  • the non-neural cell may reside in the central nervous system (CNS), for example, in the brain (such as glial cells and immune system cells, such as B cells, dendritic cells, macrophages and microglia), or may exist in an organ outside the CNS, such as cardiac, skeletal or smooth muscle (a muscle cell), liver (a hepatic cell) or kidney (a renal cell) and so forth.
  • CNS central nervous system
  • Non-neural cells include cells of the immune system, regardless of whether they reside in the CNS or elsewhere in the body of the organism.
  • a "cytoprotective cytokine” is a soluble protein (or glycoprotein) involved in the regulation of cellular proliferation and function that acts to preserve cellular function and prevent (or reduce) death of a cell in response to a stressful or otherwise aversive stimulus.
  • Cytoprotective cytokines include transforming growth factor ⁇ (TGF-/3), tumor necrosis factor a (TNF ⁇ ), and type I interferons, such as interferon ⁇ (IFN/3).
  • TGF-/3 transforming growth factor ⁇
  • TNF ⁇ tumor necrosis factor a
  • IFN/3 type I interferons
  • a “neuroprotective cytokine” is a cytoprotective cytokine that acts to preserve cellular function and reduce cell death in neural cells.
  • An "inhibitor of an acid sensing ion channel” or “ASIC inhibitor” is any molecule that reduces (e.g. , partially or completely blocks) the activity of at least one member of the ASIC family of receptors, such as ASICIa, ASICIb, ASIC2a, ASIC2b, ASIC3 and ASIC4.
  • an ASIC inhibitor can reduce the ability of an ASIC to flux ions (such as sodium, calcium, and/or potassium ions) across a cell membrane.
  • the ASIC inhibitor can be selective for an ASIC receptor, or it can globally inhibit multiple ASIC receptors.
  • Exemplary ASIC inhibitors include Tarantula psalmotoxin 1 (PcTx) and structurally related peptides. Additional details regarding ASIC inhibitors, such as PcTx and structurally related peptides, can be found in WO 06/034035, which is incorporated herein by reference for all purposes.
  • compositions are formulated for administration to human and/or animal (veterinary) subjects, and typically include one or more active component (such as one or more of the CpG oligonucleotides disclosed herein) as well as one or more additional components to facilitate administration to a subject, for the therapeutic or prophylactic treatment (prevention or reduction) of a condition or disease.
  • additional components can include pharmaceutically acceptable carriers, buffers or excipients. Pharmaceutically acceptable carriers, buffers and so forth, are well known in the art, and are described, e.g., in Remington 's Pharmaceutical Sciences, 19 th Ed., Mack Publishing Company, Easton, Pennsylvania, 1995.
  • prophylactic treatment refers to the treatment of a subject prior to the full manifestation of an event, condition or disease for the purpose of preventing or reducing the symptoms, signs or consequences of the event, condition or disease.
  • prophylactic treatment of an excitotoxic injury or hypoxia refers to the treatment of a subject prior to the occurrence of an excitotoxic or hypoxic event (that is, prior to a first excitotoxic or hypoxic event, or prior to a subsequent excitotoxic or hypoxic event, or prior to the completion or culmination of an ongoing or recurrent excitotoxic or hypoxic event) and prior to the completion of the natural consequences and/or sequelae of the event.
  • therapeutic refers to the treatment of a subject after the onset or at least partial manifestation of an event (although not necessarily following completion or full manifestation) for the purpose of reducing the symptoms, signs or consequences of the event, condition or disease.
  • a "preconditioning dose” is a dose of an effective compound, or composition containing such a compound, that protects a cell against injury or death due to an excitotoxic, ischemic or hypoxic event.
  • the dosage of the effective compound or composition varies from compound to compound and between species.
  • a suitable preconditioning dose for any compound can be determined empirically.
  • Exposure of cells to subthreshold levels (that is, at a level below that which causes injury) of a stressful (e.g., cytotoxic) stimulus can induce tolerance to subsequent events that would otherwise result in injury.
  • This effect has been termed preconditioning, and is relevant to preventing or reducing injury due to cytotoxic insult such as excitotoxic events and hypoxia (e.g. , due to ischemia) in a variety of cell and tissue types, including neural cells, muscle cell (e.g., skeletal as well as cardiac muscle cells), kidney cells and liver cells.
  • Preconditioning in the brain that is, of neural cells and other organs can be produced " following exposure to a subthreshold level of an otherwise toxic stimulus.
  • a subthreshold level of an otherwise toxic stimulus For example, brief exposure to ischemia and administration of a sub-toxic dosage of lipopolysaccharide (LPS) have been shown to elicit a protective response to subsequent ischemic events. This effect is dependent on de novo protein synthesis, and involves changes in genomic programming associated with inflammation.
  • LPS lipopolysaccharide
  • a suitable preconditioning agent such as a CpG oligonucleotide, imiquimod, or other agent that activates a TLR
  • protection against excitotoxic and/or hypoxic injury typically begins within about 10-12 hours and lasts for up to several weeks, or more. In addition, protection can be extended by repeated administration of the agent.
  • TNFa and its downstream signaling mediator, ceramide are involved in achieving a preconditioning effect, and blockade of TNFo; (with a soluble TNF receptor or fragment thereof) prevents the protective effect of preconditioning.
  • proximal members of the TNF ⁇ pathway namely TNF ⁇ and its receptors, TNFRl (p55) and TNFR2 (p75), as well as sphingomyelin-based second messengers such as ceramide, are likely mediators of the protective effects of TNF ⁇ in LPS preconditioning.
  • TNF ⁇ -activation of NF- ⁇ B may also be involved, as inflammatory molecules regulated by NF- ⁇ B, such as superoxide dismutase (SOD), have been shown to be involved in preconditioning (Bordel et al, J. Cereb. Blood Flow Metab. 20: 1190- 1196, 2000).
  • SOD superoxide dismutase
  • IFNs are a family of cytokines comprised of type I (IFN ⁇ and IFN ⁇ ) and type II (IFN ⁇ ) IFNs.
  • type I IFNs have many immunomodulatory functions.
  • IFN ⁇ / ⁇ are associated with anti-inflammatory cytokines (Shnyra et ah, J. Immunol. 160:3729-3736, 1998).
  • IFN ⁇ has been shown to improve stroke outcome following systemic administration in animal models (Veldhuis et al., J. Cereb. Blood Flow Metab. 23:1029-1039, 2003; Liu et al, Neurosci Lett. 327:146-148, 2002).
  • the mitigating role of IFN ⁇ in stroke is primarily due to its anti- inflammatory properties that reduce cell infiltration into the affected tissue via regulation of matrix metalloproteinase-9.
  • IFN ⁇ has been shown to decrease reactive oxygen species, suppress inflammatory cytokines (Hua et al, J. Neurochem. 83:1120-1128, 2002) and promote cell survival (Barca et al, J. Neuroimmunol, 139:155-159, 2003), functions that contribute to improved outcome following stroke.
  • IFN regulatory factors IFN regulatory factors
  • IRFs IFN regulatory factors
  • IRFs constitute a family of transcription factors whose functions in some instances are distinct and independent of one another, while in others, appear to be interdependent (Taniguchi and Takaoka, Curr. Opin. Immunol. 14: 111-116, 2002).
  • IRF3 binding to the interferon stimulated response element (ISRE) induces IFN ⁇ , which is involved in the early stages of preconditioning.
  • IRF3 The ability of IRF3 to transactivate IFN ⁇ in this scenario depends on NFKB as well. Interaction between these two transcription factors is extensive; IRF3-NF ⁇ B complexes have been shown to interact not only at the ISRE but at KB sites as well (Wietek et al., J. Biol. Chem. 278:50923-50932, 2003; Leung et al, Cell 118:453-464, 2004). Furthermore, many genes contain both IRSE and icB sites within their promoter regions and depend upon interaction between the two factors for transcription initiation (Genin et al., J. Immunol. 164:5352-5361, 2000). IRF3 is induced by agents that activate TLRs and is likely to mediate the cytoprotective effects of preconditioning agents.
  • Preconditioning involves a fundamental change in the genomic program or response (that is, the pattern of gene expression produced in response) to excitotoxic, ischemic and/or hypoxic injury that shifts the outcome from cell death to cell survival (Stenzel-Poore et al, The Lancet 362:1028- 1037, 2003).
  • This change in gene expression, or genomic reprogramming, in response to cytotoxic insults, such as excitotoxic, ischemic and/or hypoxic events involves a pronounced suppression of 34796
  • inflammatory cytokines for example, of inflammatory cytokines, and certain ion channels and channel regulators, e.g., K + and Ca 4+ channels, such as glutamate receptors
  • K + and Ca 4+ channels such as glutamate receptors
  • Such suppression contrasts sharply with the upregulation of mRNA by excitotoxic, ischemic and/or hypoxic events without preconditioning.
  • This change is not simply the lack of a response, but rather a reprogramming of the genomic response that involves the downregulation of genes that control metabolism, cell-cycle regulation, and, in neural cells, ion-channel activity.
  • preconditioning elicits a shift from pro-inflammatory to anti- inflammatory cytokines.
  • Preconditioning in macrophages involves attenuation of NF- ⁇ B and AP-I and enhanced expression of the signaling mediators, IRAK-M and SOCS-I (Kobayashi et al., Cell 110:191-200, 2002; Nakagawa et al., Immunity 17:677-687, 2002; Kinjyo et al, Immunity 17:583-591, 2002). Similar genomic reprogramming is also likely to be involved in preconditioning in cardiac tissue (Meng et al., Am. J. Physiol. 275:C475-483, 1998), although the specific genes can differ ⁇ e.g., HSP70, c-jun, c-fos).
  • the present disclosure provides methods for preconditioning cells by systemically administering an agent that binds to a Toll-like receptor and thereby induces changes in the genomic program of certain cells, for example, as described above by altering the nature and amount of cytokines produced.
  • an agent that activates a TLR e.g., a CpG oligonucleotide
  • Binding of the agent to TLR expressed on the surface of target cells results in genomic reprogramming and in the case of the above mentioned immune cells, can induce an alteration in the cytokine secretion profile, including the induction of cytoprotective cytokines, such as TNF- ⁇ , type I interferons (e.g., IFN- ⁇ , IFN- ⁇ ) and/or TGF-0.
  • cytoprotective cytokines such as TNF- ⁇ , type I interferons (e.g., IFN- ⁇ , IFN- ⁇ ) and/or TGF-0.
  • the agent(s) that activate a TLR can be administered in combination with an ASIC inhibitor to further increase protection and reduce injury by excitotoxic, ischemic and/or hypotoxic events.
  • ASIC acid sensing ion channel
  • PcTx psalmotoxin 1
  • ⁇ Psalmopoeus cambridgei acid sensing ion channel
  • the protective effect of preconditioning is substantially enhanced by administration of the preconditioning agent (such as a CpG oligonucleotide or imiquimod) in combination with an ASIC inhibitor.
  • the ASIC inhibitor is typically administered in one or more doses during or after the onset of an excitotoxic, ischemic and/or hypoxic event; most commonly, in the first few hours following the onset or initiation of the event.
  • the ASIC inhibitor can be systemically or locally administered (e.g., via an intrathecal administration route).
  • the ASIC inhibitor binds to one or more ASIC receptor channels and reduces (partially or completely blocks) the receptor's ability to transfer ions across a cell membrane. By blocking ion flux, the ASIC inhibitor reduces the excitotoxic element of the event, reducing injury to cells and tissues.
  • neural cells including, e.g. , hippocampal neurons and cortical neurons
  • muscle cells including cardiac and striated muscle cells
  • hepatic cells and renal cells can be protected against injury and death by administering a preconditioning agent (such as a CpG oligonucleotide) prior to the occurrence of an excitotoxic, ischemic or hypoxic event.
  • a preconditioning agent such as a CpG oligonucleotide
  • a preconditioning agent is typically administered to a subject that has been identified as having (e.g., diagnosed with) one or more risk factors indicative of an increased likelihood, relative to the general population or to a subject without the risk factor, of having an excitotoxic, ischemic and/or hypoxic event.
  • Excitotoxic injury results from excessive stimulation of cells (typically neural cells in the CNS) by certain neurotransmitter (e.g., glutamate) receptors.
  • Excitotoxic injury can be a result of a condition that causes excessive chemical or electrical activity in the brain or it can be a result of conditions that cause a decrease in inhibitory or regulatory functions of the brain.
  • Excitotoxic injury in the brain is associated with a variety of conditions with disparate etiologies and symptoms, including epilepsy, traumatic brain injury and Alzheimer's disease. For example, in addition to medical indications such as epilepsy or Alzheimer's disease, non-medical indicators of risk, pertaining to behaviors or activities that are statistically associated with an increased likelihood of injuries that can include an excitotoxic component.
  • traumatic brain injury frequently involves an excitotoxic (and can also include) a hypoxic component.
  • participation in activities that increase the risk of traumatic brain injury is an indicator that can be used to select a subject for administration of a preconditioning agent (such as a CpG oligonucleotide).
  • a preconditioning agent such as a CpG oligonucleotide
  • activities include, for example, motorcycle riding, motor vehicle racing, skiing, contact sports (such as, football, hockey, rugby, soccer, lacrosse, martial arts, boxing and wrestling), and the like.
  • impacts or wounds resulting from gunshot or explosives frequently cause traumatic brain injury. Accordingly, activities that are associated with an increased risk of gunshot wounds or injury caused by explosive devices (for example, in combat situations) are an indicator of risk that can be used to select a subject for treatment according to the methods disclosed herein.
  • hypoxia is typically associated with ischemic events in the CNS or elsewhere in the cardiovasculature, (such as cerebrovascular ischemia, or stroke, myocardial ischemia due to narrowing or blockage of the vessels of the heart, iatrogenic ischemia, due to surgical procedures, and the like).
  • hypoxia can occur in utero due to conditions such as inadequate placental function (for example, due to abrupio placentae), preeclamptic toxicity, prolapse of the umbilical cord, or complications from anesthetic administration.
  • injury by some hypoxic events involves an excitotoxic component as well as a hypoxic component.
  • cardiovascular signs and symptoms such as atrial fibrillation, angina pectoris, hypertension, transient ischemic episodes and prior stroke
  • a preconditioning agent such as a CpG oligonucleotide
  • surgical procedures especially those specifically involving the cardiovascular system, such as endarterectomy, pulmonary bypass and coronary artery bypass surgeries, are indicators of risk that can be used to select a subject for administration of a preconditioning agent.
  • oligonucleotides containing an unmethylated CpG motif are administered to a subject for the purpose of preconditioning one or more cells (or cell types, or tissues, or organs) to protect against a cytotoxic insult, such as an excitotoxic injury, ischemia or hypoxia.
  • a cytotoxic insult such as an excitotoxic injury, ischemia or hypoxia.
  • CpG oligonucleotides are oligonucleotides that contain at least one unmethylated cytosine-guanine dinucleotide sequence.
  • the production and use of CpG oligonucleotides are known in the art, and described, for example, in US Patents No. 6,194,388 and 6,406,705. Without being bound by theory, all compositions and methods of producing them disclosed in US Patents No. 6,194,388 and 6,406,705 are incorporated herein by reference for all purposes.
  • a CpG ODN is between about 8 and 100 nucleotides in length.
  • the CpG ODN is at least 10, or at least 12 nucleotides in length.
  • a CpG ODN is no more than about 40 nucleotides in length.
  • longer nucleotides can be employed, the cost of production increases with length with no significant benefit in terms of activity.
  • CpG ODN longer than 50 nucleotides, or 60 nucleotides, or even 70, or 80, or 90, or 100 nucleotides or more in length, there is little benefit in doing so.
  • the unmethylated CpG is flanked by complementary nucleotides, such that a palindromic sequence capable of hairpin formation (via base pairing interactions) around the CpG dinucleotide is included in the sequence of the CpG ODN.
  • a palindromic sequence capable of hairpin formation (via base pairing interactions) around the CpG dinucleotide is included in the sequence of the CpG ODN.
  • the inclusion of palindromic sequences flanking the unmethylated CpG dinucleotide is particularly desirable when using short oligonucleotides (e.g., 10 or 12 nucleotides in length).
  • CpG oligonucleotides bind to Toll-like receptor 9 (TLR9) on the surface of cells in a wide variety of tissues and/or organs (Nishimura and Naito, Biol. Pharm, Bull. 28:886-892, 2005). Binding of a CpG oligonucleotide to TLR9 initiates a signaling pathway mediated by MyD88 and p38- MAPK, which induces expression of NF- ⁇ B and IFNj3, among other genomic changes.
  • CpG oligonucleotides can be divided into at least three classes based on their structural and functional attributes.
  • A-Class CpG oligonucleotides (exemplified by SEQ ID NO:2) stimulate dendritic cells to make large amounts of IFNcebut have a weak effect on B cells.
  • B-Class CpG oligonucleotides (exemplified by SEQ ID NO:3 and SEQ ID NO:5) induce IFNq production to a lesser extent, but very strongly induce B cell activation and antibody production.
  • C-Class oligonucleotides (exemplified by SEQ ID NO:4) combine the effects of A- and B-Class oligonucleotides by exhibiting strong B cell, IFTSta stimulation, and natural killer cell activation. Any of these classes can be used to elicit a protective response in the context of the preconditioning methods disclosed herein.
  • oligonucleotides can be synthesized de novo using any of a number of procedures well known in the art.
  • the /3-cyanoethyl phosphoramidite method eaucage and Caruthers, TeL Let. 22:1859, 1981
  • nucleoside H-phosphonate method Gagg et al, TeL Let. 27: 4051-4054, 1986; Froehler et al., Nucl. Acid. Res. 14: 5399-5407, 1986; Garegg et al, TeL Let. 27: 4055-4058, 1986; Gafffney et al. , TeL Let.
  • oligonucleotides can be prepared from existing nucleic acid sequences ⁇ e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.
  • oligonucleotide stabilization can be accomplished via phosphate backbone modifications.
  • an ODN can be rendered nuclease resistant by phosphorothioate modification (that is, at least one of the phosphate oxygens is replaced by sulfur) of one or more internucleotide linkages. In some cases, the terminal internucleotide linkages are phosphorothioate modified.
  • Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H phosphonate chemistries.
  • oligonucleotides include: nonionic DNA analogs, such as alkyl- and aryl- phosphonates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation. Aryl- and alkyl- phosphonates can be made (for example, as described in U.S. Patent No.
  • alkylphosphotriesters in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574 can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann and Peyman, Chem. Rev. 90:543-584, 1990; Goodchild, Bioconjugate Chem. 1 :165-187, 1990).
  • CpG oligonucleotides can be associated with a molecule that enhances binding to target cell surfaces and/or increased cellular uptake by target cells to form an "oligonucleotide delivery complex."
  • Oligonucleotides can be ionically, or covalently associated with appropriate molecules using techniques which are well known in the art.
  • a variety of coupling or crosslinking agents can be used, including protein A, carbodiimide, and N-succinimidyl-3-(2- pyridyldithio) propionate (SPDP).
  • SPDP N-succinimidyl-3-(2- pyridyldithio) propionate
  • oligonucleotides can be encapsulated in liposomes or virosomes using well-known techniques to facilitate delivery.
  • Oligonucleotides containing at least one unmethylated CpG dinucleotide can be administered to a subject in vivo as a preconditioning agent to prevent or reduce the adverse effects of excitotoxic injury, ischemia and/or hypoxia.
  • CpG oligonucleotides are systemically administered to a subject at risk of one or more of excitotoxic, ischemic and/or hypoxic injury prior to an event that is likely to cause such injury.
  • an effective amount of an appropriate oligonucleotide (alone or formulated as an oligonucleotide delivery complex) can be administered to a subject by any mode allowing the oligonucleotide to bind to appropriate receptors on the surface of target cells (e.g., TLR9).
  • target cells e.g., TLR9
  • Formulation and dosages of compositions containing CpG oligonucleotides are discussed in detail herein below.
  • TLRs are expressed on the surface of cells in a wide variety of tissues, including brain, heart, kidney, liver, lung, skeletal muscle, spleen and thymus. In addition overlapping subsets of TLRs are expressed on different cells of the immune system.
  • TLR9 is highly expressed on human dendritic cells and B cells, whereas TLR2 is most highly expressed on monocytes, as is TLR4.
  • TLRl is expressed well on monocytes, dendritic cells and B cells, as well as on NK cells and T cells.
  • TLR 5 is also expressed on T cells, NK cells and monocytes, but little expression is seen on B cells or monocytes.
  • TLR6 is expressed on all of the above cell lineages, with expression being highest on B cells.
  • TLR7 is expressed on monocytes, B cells and dendritic cells, with highest expression in dendritic cells.
  • any agent that activates a Exemplary agents that stimulate TLRs (other than CpG oligonucleotides) and that are suitable for administration as preconditioning agents include non-toxic analogs of LPS, which activate TLR4, and MALP-2 a TLR2 agonist, and imiquimod a TLR7/8 agonist.
  • imiquimod and other imidazoquinoline compounds, such as R-848) bind to and activate TLR7 in mice, and TLR7 and TLR8 in humans (Hemmi et al, Nat Immunol, 3:196-200, 2002; Jurk et al., Nat Immunol. 3:499, 2002).
  • these compounds have been used as antiviral and antitumour agents, typically at doses ranging between 0.25 and 5 mg/kg.
  • Preconditioning doses of imiquimod typically range from about 0.002 mg/kg (such as 0.005 mg/kg, or 0.008 mg/kg, or about 0.01 mg/kg, or about 0.02 mg/kg, or about 0.05 mg/kg) to about 0.1 mg/kg in humans, such as about 0.08 mg/kg).
  • Administration of a preconditioning dose of imiquimod (and/or other imidazoquinoline compounds or derivative(s) that bind to and activate TLR7/8) to a subject at risk of an excitotoxic injury, ischemia and/or hypoxia, prior to such a cytotoxic insult protects against cell injury and death.
  • imiquimod (and related compounds or derivatives) can be used as an alternative to, or in combination with CpG oligonucleotides as preconditioning agents.
  • Additional preconditioning agents can be identified using a reporter system in which binding and activation of a selected TLR and induction of NF- ⁇ B is detected using an NF-/cB responsive reporter construct.
  • Cell lines such as HEK293, stably transfected with the components necessary for signaling via a selected TLR are transfected with an NFKB inducible reporter plasmid, ⁇ NiFty2- SEAP (InvivoGen, San Diego).
  • This plasmid contains an engineered promoter that combines five NFKB sites with the proximal ELAM (endothelial cell-leukocyte adhesion molecule) promoter upstream of a reporter gene encoding secreted alkaline phosphatase (SEAP).
  • SEAP secreted alkaline phosphatase
  • SEAP is extremely heat stable and can be detected spectrophotometrically, either colorimetrically or by detecting a luminescent product, e.g., using a PHOSPHA-LIGHTTM chemiluminescence kit (Applied Biosystems, BP3000).
  • the substrate CSPD [3-(4-methoxyspiro[l,2-dioxetane-3,2'(5 '- chloro)-tricyclo(3.3.1.13,7)decane]-4-yl)phenyl phosphate] is dephosphorylated by SEAP, and the resulting unstable dioxetane anion decomposes and emits light at a wavelength of 477 nm.
  • the light signal is quantitated in a microplate luminometer and is linear up to 5 orders of magnitude and proportional to the concentration of SEAP.
  • the extent of TLR activation can be quantified by collecting supernatant and determining the concentration of SEAP via this assay.
  • the transfected cell line expressing the selected TLR and the parental HEK293 cells each carrying the NF- ⁇ B reporter construct are stimulated (for between 12 and 24 hours, e.g., for approximately 18 hours or overnight) with varying doses of a test agent.
  • each test agent is tested at multiple doses to determine a dose/response curve.
  • supernatant is collected and NF- ⁇ B activity is measured using an alkaline phosphatase assay.
  • the preconditioning capacity of the agent can be confirmed using an in vitro model of stroke.
  • Primary mouse cortical neuronal cultures are pretreated with media or the identified test agent at a suitable dose determined from the dose/response curve. Approximately 24 hours later, the growth medium is replaced with PBS containing 0.5 mM CaCl 2 and 5 mM MgCl 2 , pH 7.4.
  • the neuronal cultures are placed in an anaerobic chamber (Forma Scientific) containing an atmosphere of 85% N 2 , 5% H 2 , 10% CO 2 that is maintained at 35°C (oxygen-glucose deprivation-treatment, "OGD”). Following OGD-treatment (3 hours), the PBS is replaced with Minimum Essential Medium (MEM) and the cultures are returned to normoxic conditions.
  • OGD oxygen-glucose deprivation-treatment
  • Percent cell death is then determined. For example, background cell death can be determined using medium and the test agent alone without OGD, to determine the effect of each compound on cell viability. LPS (l ⁇ g/ml) preconditioning of a TLR4 transfected cell line can be used as a positive control for neuronal protection. Cell death is assessed approximately 24 hours following OGD using, for example, the fluorescent exclusion dye propidium iodide. The percent cell death is quantified, and differences between means (% cell death) in the cells contacted with the test agent and controls are compared for significance, e.g., using between groups factorial ANOVA grouped on treatment (media vs. test agent) and hypoxic status (no OGD vs. OGD).
  • Agents that exhibit a significant protective effect are suitable as preconditioning agents to protect against excitotoxic injury and/or hypoxia.
  • the methods described above can be use to screen libraries of compounds, such as Mixture Based Positional Scanning Libraries, for preconditioning agents.
  • a Mixture-Based Positional Scanning Library is designed to provide information on the activity of collections of systematically arranged compounds numbering in the thousands to millions. The positional scanning technology has been used successfully to identify novel enzyme inhibitors, receptor agonists and antagonists, antimicrobial, antifungal, and antiviral compounds (Houghten et al., J. Med. Chem.
  • Each positional scanning library is designed around a core pharmacophore.
  • core pharmacophores in positional scanning libraries are chosen based on the following criteria: the core structure can be produced under straightforward and inexpensive synthetic conditions; the core structure can have numerous incorporated functional diversity elements; and the core structure is known or purported to be of biological importance.
  • Each positional scanning sub-library contains positions that enable structural variations around the central core. Screening data from a library provides extensive structure-activity relationship information and enables identification of active individual compounds. Thus the individual structural components and their representative contributions to total biological activity within the positional scanning library are revealed.
  • Mixture- based small molecule positional scanning combinatorial libraries (Mixture Sciences, Inc.) can be screened to identify agents that activate a selected TLR. Typically, human TLR are utilized to identify agents with optimal activity characteristics for human receptors.
  • a transfected cell line expressing the selected TLR is first contacted with pools of libraries to identify libraries with active constituents.
  • Library mixtures and library pools are formulated at 1 mg/ml in 10% dimethyl formamide (DMF).
  • DMF dimethyl formamide
  • Cell lines are tested for toxicity to DMF at concentrations of 1% or less.
  • Library pools are applied at the maximum practical concentration, determined by the cell line's tolerance to DMF.
  • the preconditioning composition(s) and regimens are administered in combination with at least one ASIC inhibitor.
  • ASIC inhibitors are agents that reduce (that is, partially or completely block) ion flux mediated by one or more acid sensing ion channel (ASIC).
  • the ASIC inhibitor is a peptide that is a conotoxin from an arachnid and/or cone snail species.
  • Exemplary ASIC inhibitors are cystine knot peptides, such as psalmotoxin 1 (PcTx) of the tarantula Psalmopoeus cambridgei, and structurally related peptides.
  • Cystine knot peptides typically include an arrangement of six or more cysteines that can assemble into a "knot" conformation that includes (1) a ring formed by two disulfide bonds and their connecting backbone segments, and (2) a third disulfide bond that threads through the ring.
  • the PcTx peptide is represented by the sequence EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT (SEQ ID NO:6) , Exemplary ASIC inhibitors are described in WO 06/034035, which is incorporated herein by reference.
  • the ASIC inhibitor is a structurally related peptide (that is, the peptide that is structurally related to PcTx) that differs by at least one deletion, insertion, and/or substitution of an amino acid.
  • the structurally related peptide can be shorter or longer than the PcTx peptide of SEQ ID NO:6 by one, two, three, four, five, six, seven, eight, nine, ten or more amino acids.
  • the structurally related peptide can have one more amino acid substitutions.
  • a structurally related peptide has at least about 50% sequence identity (such as about 75%, 80%, 90% or 95% sequence identity), and/or at least about 50% sequence similarity (such as about 75%, 80%, 90% or 95% sequence similarity) with PcTx (SEQ ID NO:6).
  • sequence identity such as about 75%, 80%, 90% or 95% sequence identity
  • sequence similarity such as about 75%, 80%, 90% or 95% sequence similarity
  • Additional peptides that are structurally related to PcTx can be tested for their ability to inhibit ASIC proteins selectively and/or for an effect on ischemia.
  • Any suitable test system(s) may be used to perform this testing, including any of the cell-based assay systems and/or animal model systems described, e.g., in WO 06/034035.
  • the preconditioning compositions (medicaments) disclosed herein can be administered to a subject to protect against excito toxic injury, ischemia and/or hypoxia. Accordingly, the compositions are administered to a subject at risk of an excitotoxic, ischemic or hypoxic event to prevent or reduce the deleterious effects of such an event or occurrence. Administration of the composition is not necessarily deemed to alter the likelihood of occurrence of any cytotoxic insult, rather administration of the preconditioning composition alters or modifies the outcome following the occurrence of such an event by inducing cellular changes (e.g., in the genomic program) that reduce, prevent or ameliorate the effects of the excitotoxic, ischemic and/or hypoxic event.
  • cellular changes e.g., in the genomic program
  • the preconditioning compositions include at least one agent that binds to a TLR.
  • the pharmaceutical compositions include one or more agent that is a ligand of a TLR.
  • the ligand is selected to be appropriate for the subject receiving the composition. For example, when administering a preconditioning agent to a human subject, the agent is selected to be a ligand that binds to and activates a human TLR. Similarly, if the subject to be treated is a non- human animal, the agent is selected to bind to and activate a TLR of that species of animal.
  • the composition includes a single TLR ligand; in other instances, the composition includes more than one TLR ligand. Where a composition includes more than one TLR ligand, the composition can include multiple agents that bind to and activate a single TLR (optionally with different signaling results) or that bind to and activate different TLRs.
  • the quantity of the TLR binding and activation agent (such as a CpG oligonucleotide or imiquimod) included in the pharmaceutical composition is an amount determined to provide a preconditioning effect.
  • a preconditioning composition can include an amount of a CpG oligonucleotide sufficient to provide at least about 0.005 mg of the CpG oligonucleotide per kg body weight of the subject (0.005 mg/kg).
  • compositions include an amount of a CpG oligonucleotide from about 0.008 mg/kg (for example, about 0.01 mg/kg, or about 0.02 mg/kg, or about 0.025 mg/kg, or about 0.05 mg/kg) to about 0.2 mg/kg (for example, about 0.08 mg/kg, or about 0.09 mg/kg, or about 0.10 mg/kg, or about 0.12 mg/kg or about 0.15 mg/kg).
  • a the composition can be formulated to include at least about 0.1 mg (100 ⁇ g) of a CpG oligonucleotide, to about 100 mg of the CpG oligonucleotide, in a single dose.
  • the TLR binding agent is imiquimod, which is administered at comparable doses (e.g., between about 0.005 and 0.2 mg/kg, such as between about 0.01 and 0.10, e.g., at approximately 0.05-0.08 mg/kg). Suitable dose ranges and dosage can be determined by one of skill in the art for any TLR binding agent with a preconditioning effect.
  • Methods for formulating and delivering CpG oligonucleotides are provided in US Patents No: 6,194,388 and 6,406,705. The methods of formulating and administering CpG oligonucleotides disclosed therein are incorporated herein by reference.
  • the quantity of the ASIC inhibitor (e.g. , PcTx or a structurally related peptide) included in a pharmaceutical composition is an amount determined to provide a beneficial (injury reducing) effect.
  • a pharmaceutical composition when administered to a subject (such as a human subject) in one or more doses a pharmaceutical composition can include an amount of an ASIC inhibitor sufficient to provide at least about O.OOl ⁇ g of the ASIC inhibitor per kg body weight of the subject.
  • the ASIC inhibitor can be administered in a quantity sufficient to provide about O.Ol ⁇ g/kg body weight, such as at least about 0.005 ⁇ g/kg up to about 0.1mg/kg. Actual doses can be determined by one of skill in the art for any ASIC inhibitor with a protective effect.
  • the composition typically includes one or more pharmaceutically acceptable constituents, such as a pharmaceutically acceptable carrier and/or pharmaceutically acceptable diluent.
  • preparation of a preconditioning composition entails preparing a pharmaceutical composition that is essentially free of pyrogens, as well as any other impurities that could be harmful to humans or animals.
  • the pharmaceutical composition contains appropriate salts and buffers to render the components of the composition stable and facilitate administration to a subject.
  • Such components can be supplied in lyophilized form, or can be included in a diluent used for reconstitution of a lyophilized form into a liquid form suitable for administration.
  • a suitable solid carrier is included in the formulation.
  • Aqueous compositions typically include an effective amount of the preconditioning agent dispersed (for example, dissolved or suspended) in a pharmaceutically acceptable diluent or aqueous medium.
  • Pharmaceutically acceptable molecular entities and compositions generally do not produce an adverse, allergic or other undesirable reaction when administered to a human or animal subject.
  • pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like.
  • a pharmaceutically acceptable carrier or diluent can include an antibacterial, antifungal or other preservative. The use of such media and agents for pharmaceutically active substances is well known in the art.
  • preconditioning compositions Except insofar as any conventional media or agent is incompatible with production of a preconditioning response, its use in the preconditioning compositions is contemplated. In some cases (for example, when liquid formulations are deemed desirable, or when the agent is reconstituted for multiple doses in a single receptacle), these preparations contain a preservative to prevent or inhibit the growth of microorganisms.
  • compositions and formulations suitable for pharmaceutical delivery of inactivated pathogens are known to those of ordinary skill in the described, e.g., in Remington 's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of inactivated pathogens.
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like
  • solid compositions e.g., powder, pill, tablet, or capsule forms
  • conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
  • compositions to be administered can contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.
  • nontoxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.
  • the pharmaceutical compositions can include one or more of a stabilizing detergent, a micelle-forming agent, and an oil.
  • Suitable stabilizing detergents, micelle- forming agents, and oils are detailed in U.S. Patents No. 5,585,103; 5,709,860; 5,270,202; and 5,695,770.
  • a stabilizing detergent is any detergent that allows the components of the emulsion to remain as a stable emulsion.
  • Such detergents include polysorbate, 80 (TWEEN) (Sorbitan-mono-9- octadecenoate-poly(oxy-l,2-ethanediyl; manufactured by ICI Americas, Wilmington, DE), TWEEN 006/034796
  • TWEEN 20TM TWEEN 60TM
  • ZwittergentTM 3-12 TEEPOL HB7TM
  • SPAN 85TM SPAN 85TM.
  • These detergents are typically provided in an amount of approximately 0.05 to 0.5%, such as at about 0.2%.
  • a micelle forming agent is an agent which is able to stabilize the emulsion formed with the other components such that a micelle-like structure is formed.
  • Such agents generally cause some irritation at the site of injection in order to recruit macrophages to enhance the cellular response.
  • examples of such agents include polymer surfactants described by, e.g., Schmolka, J. Am. Oil. Chem. Soc. 54:110, 1977, and Hunter et al., J. Immunol 129:1244, 1981, and such agents as PLURONICTM L62LF, LlOl, and L64, PEGlOOO, and TETRONICTM 1501, 150Rl, 701, 901, 1301, and 130Rl.
  • the chemical structures of such agents are well known in the art.
  • the agent is chosen to have a hydrophile-lipophile balance (HLB) of between 0 and 2, as defined by Hunter and Bennett (J. Immun. 133:3167, 1984).
  • HLB hydrophile-lipophile balance
  • the agent can be provided in an effective amount, for example between 0.5 and 10%, or in an amount between 1.25 and 5%.
  • the oil included in the composition is chosen to promote the retention of the pathogen in oil- in-water emulsion, and preferably has a melting temperature of less than 65 0 C, such that emulsion is formed either at room temperature, or once the temperature of the emulsion is adjusted to room temperature.
  • oils include squalene, squalane, EICOSANETM, tetratetracontane, glycerol, and peanut oil or other vegetable oils.
  • the oil is provided in an amount between 1 and 10%, or between 2.5 and 5%.
  • the oil should be both biodegradable and biocompatible so that the subject can break down the oil over time, and so that no adverse affects, such as granulomas, are evident upon use of the oil.
  • compositions can be prepared for use in preconditioning or prophylactic regimens and administered to human or non-human subjects to elicit a protective response against an excitotoxic, ischemic or hypoxic event.
  • compositions described herein can be administered to a human (or non-human) subject to elicit a protective response against stroke or other ischemic events.
  • a pharmaceutical composition for example, containing a CpG oligonucleotide
  • administration is intranasal.
  • the preconditioning composition can be administered in solid form, e.g., as a powder, pellet or tablet.
  • the preconditioning agent can be administered as a powder using a transdermal needleless injection device, such as the helium- powered POWDERJECT® injection device.
  • This apparatus uses pressurized helium gas to propel a powder formulation of a preconditioning composition, e.g., containing a CpG oligonucleotide, at high speed so that the particles perforate the stratum corneum and contact cells in the epidermis.
  • Polymers can be also used for controlled release.
  • Various degradable and nondegradable polymeric matrices for use in controlled drug delivery are known in the art (Langer, Accounts Chem. Res. 26:537, 1993).
  • the block copolymer, polaxamer 407 exists as a viscous yet mobile liquid at low temperatures but forms a semisolid gel at body temperature (Johnston et al, Pharm. Res. 9:425, 1992; and Pec, J. Parent. ScL Tech. 44(2):58, 1990).
  • hydroxyapatite has been used as a microcarrier for controlled release (Ijntema et al, Int. J. Pharm. 112:215, 1994).
  • liposomes are used for controlled release as well as drug targeting of the lipid- capsulated drug (Betageri et al, Liposome Drug Delivery Systems, Technomic Publishing Co., Inc., Lancaster, PA, 1993).
  • Numerous additional systems for controlled delivery of therapeutic compositions are known (e.g., U.S. Patents No. 5,055,303; 5,188,837; 4,235,871; 4,501,728; 4,837,028; 4,957,735; 5,019,369; 5,055,303; 5,514,670; 5,413,797; 5,268,164; 5,004,697; 4,902,505; 5,506,206; 5,271,961; 5,254,342; and 5,534,496).
  • the preconditioning compositions are administered prior to the occurrence of an excitotoxic, ischemic or hypoxic event (or prior to an increase in the likelihood of such an event).
  • the composition is administered at least 10 hours prior to the event or activity, in order to fully realize the preconditioning effect of administration.
  • the composition is administered at least 24 hours before the event or activity.
  • the protective effects of a single administration of a preconditioning agent, such as a CpG oligonucleotide last for greater than one week (e.g., up to about 10 days, or more).
  • the composition is given prior to the commencement of the event, such as about 10 hours, or about 12 hours, or about 24 hours prior to the event or activity, and can be given up to about 1 week prior to the event, and in some cases up to about 10 days or more prior to the event.
  • a recurrent event such as repeated engagement in a contact sport
  • multiple administrations are given, the ultimate dose (that is, the most recent dose prior to the event) being given prior (such as, at least 10 hours, or up to about 1 week, prior) to the event or activity.
  • compositions can be formulated and administered on a continuous basis, for example using a pump (or other intravenous or intrathecal) infusion method.
  • the individual treatment regimen can be customized to the particular event or activity, such that the protective effects of the preconditioning dose of the agent (such as a CpG oligonucleotide) are optimized under the particular circumstances for the particular subject.
  • the preconditioning regimen can favorably be combined with administration of an ASIC inhibitor, such as PcTx or a structurally related peptide.
  • an ASIC inhibitor such as PcTx or a structurally related peptide.
  • the ASIC inhibitor is administered (to a subject treated with a preconditioning agent as described above) after the onset of an excitotoxic, ischemic and/or hypoxic event. It will be appreciated by one of skill in the art, that such events can be ongoing after their onset, and that it is often desirable to initiate treatment with an ASIC inhibitor at an early time following initiation or detection (e.g., diagnosis) of the event.
  • an ASIC inhibitor can be administered to a subject following onset (or detection of onset) of an excitotoxic, ischemic and/or hypoxic event.
  • Administration of the ASIC inhibitor can be initiated as soon as feasible (e.g., immediately) following detection or onset of the event, or within about 1 hour, or within about three hours, or within about five hours (and so forth). While early acute administration is generally desirable, it can be beneficial to initiate treatment with the ASIC inhibitor at later time-points, such as approximately 10 hours, or 12 hours, or even 24 hours following onset or detection of the excitotoxic, ischemic and/or hypoxic event.
  • One or more doses of the ASIC inhibitor can be administered systemically, or to a specified location (such as intraventricularly into one or more ventricles of the brain).
  • the route of administration can be optimized to the particular circumstances by one of skill in the art based on the site and nature of the event.
  • the preconditioning agent and the ASIC inhibitor are administered in separate formulations.
  • the ASIC inhibitor and at least one dose of the preconditioning agent can be co-administered (e.g., in the same or different formulations).
  • Example 1 Preconditioning with CpG oligonucleotide confers neuroprotection in an in vitro ischemia model
  • This example provides an exemplary in vitro model of neuronal ischemia, and demonstrates that preconditioning with CpG oligonucleotides protects against hypoxia.
  • Cortical neuronal cultures were prepared as described Jin et ah, Neruochem. Res. 27:1105-1112, 2002) from E-16 mouse pups (C57B1/6, Jackson labs). In brief, cortices were dissected and separated from meninges, olfactory bulbs, basal ganglia and hippocampi, and the cortices digested in 0.05% trypsin-EDTA for 15 min at 37 0 C. Cells were triturated and single cell suspension was plated at density of 5 x 10 5 cells/ml.
  • Neurobasal A medium Invitrogen, Carlsbad
  • Neuronal enrichment was determined by staining for neurons, microglia and astrocytes with cell specific markers.
  • OGD oxygen-glucose-deprivation
  • OGD was performed by replacing medium with PBS containing 0.5 mM CaCl 2 and 5 mM MgCl 2 , pH 7.4, and then placing the neuronal cultures in an anaerobic chamber (Forma Scientific) containing an atmosphere of 85% N 2 , 5% H 2 , 10% CO 2 maintained at 35°C. Following OGD-treatment (3 hours), PBS was replaced with Minimum Essential Medium (MEM) and the cells returned to normoxic conditions. Percent neuronal cell death was determined by propidium iodide staining in two different fields of view in duplicate, compared to total DAPI staining in identical fields.
  • MEM Minimum Essential Medium
  • the exemplary oligodeoxynucleotide containing an unmethylated CpG motif confers neuroprotection against oxygen-glucose deprivation in mouse neuronal cultures.
  • Example 2 Preconditioning with an exemplary CpG oligonucleotide in an in vivo
  • This example demonstrates that prophylactic administration of a composition containing a CpG oligonucleotide is neuroprotective in a mouse model of stroke.
  • Preconditioning agent (20 ⁇ g CpG oligonucleotide (SEQ ID NO:1) in artificial cerebrospinal fluid (aCSF) or aCSF alone (control) was administered intraperitoneally to subject mice 72 hours prior to middle cerebral artery occlusion (MCAO) as described below.
  • aCSF artificial cerebrospinal fluid
  • MCAO middle cerebral artery occlusion
  • CBF Cerebral blood flow
  • body temperatures was kept constant at 37 0 C with a heating pad controlled by a thermostat.
  • Body weights were monitored prior to and following MCAO.
  • Neurological testing is performed prior to sacrifice as published previously (Hill et ah, Brain Res. 820:45-54, 1999).
  • Motor Functions Tests Following pretreatment and/or ischemia/reperfusion, damage due to stroke is assessed using several behavioral indices of neurological function.
  • the corner test correlates with infarct volume and reveals post-infarct recovery (Wang et ah, Stroke 35:1732-1737, 2004).
  • the test measures the extent to which the mouse favors (turns toward) the ipsilateral side after moving into a confining corner. The assessment is conducted as previously described (Zhang et ah, J. Neurosci Methods 117:207-214, 2002). Each mouse is tested 10 times per session.
  • the footfault test which assesses forelimb dysfunction, does not predict infarct size but reflects recovery after MCAO (Wang et ah, Stroke 35:1732-1737, 2004) and neuroprotection (Gibson and Murphy, J. Cereb.
  • mice are assessed for missteps while walking on an elevated wire grid. Data (footfaults) are expressed as a fraction of the total number of steps taken (Zhang et ah, J. Neurosci Methods 117:207-214, 2002).
  • the tactile adhesive removal test which probes somatosensory function, is conducted as described (Lindner et ah, J. Neurosci. 23:10913-10922, 2003). Briefly, small adhesive paper spots are attached to the distal portion of each forelimb and the time required to remove the paper with the mouth is determined (3 trials per sessions separated by 1 minute each). Additionally, mice are evaluated for neurological symptoms using other standard indicia of mouse behavior.
  • mice were anesthetized with isoflurane and perfused with heparinized buffer to remove cells in the blood (Ford et ah, J. Immunol. 154:4309- 4321, 1995).
  • Perfused brains were placed on a tissue slicer and sectioned into 1 mm thick coronal slices. To visualize the region of infarction, sections were stained with 1.5%, 2,3,4, triphenyltetrazolium chloride (TTC) in 0.9% phosphate buffered saline (Bederson et ah, Stroke 17: 1304-1308, 1986).
  • TTC triphenyltetrazolium chloride
  • Infarct size determination was performed using a computerized image analysis system according to principles described previously to eliminate edema measurement artifacts (Swanson et ah, J. Cereb. Blood Flow Metab. 10:290-293, 1990). As shown graphically in FIG. 2, percent infarct was significantly decreased in mice treated with a preconditioning dose of an exemplary CpG oligonucleotide.
  • Example 3 Preconditioning with CpG ODNs combined with PcTx in an in vivo Ischemic/Reperfusion Model
  • mice were intraperitoneally injected with CpG ODNs (0.8 ⁇ g/kg) or saline 24 hr prior to MCAO. Mice underwent 60 min MCAO and were treated as follows: no treatment; a-CSF intraventricular injection (icv), or PcTx (0.05 pmol) intrventricular injection 1 hour after reperfusion. All percent reductions in infarct damage were calculated from the saline control group. All experimental treatments reduced infarct damage (Student's T test pO.Ol, statistical analysis compared each experimental group to the control saline). As shown graphically in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour protéger des cellules contre des agressions cytotoxiques. Ces procédés consistent à administrer à un sujet une composition qui comprend un agent se liant à un récepteur de type Toll et activant ce dernier, puis éventuellement à administrer un inhibiteur des ASIC. Ces procédés peuvent s'appliquer pour protéger des cellules neurales et non neurales. Cette invention concerne par exemple des procédés pour protéger une cellule neurale contre une lésion cérébrale excitotoxique. Ladite invention concerne également des procédés pour préparer des médicaments utilisés pour traiter de manière prophylactique une lésion excitotoxique, une ischémie et/ou une hypoxie. En outre, cette invention concerne des compositions utilisées dans le cadre desdits procédés.
PCT/US2006/034796 2005-09-09 2006-09-08 Agents neuroprotecteurs Ceased WO2007030580A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71588105P 2005-09-09 2005-09-09
US60/715,881 2005-09-09
US80183006P 2006-05-19 2006-05-19
US60/801,830 2006-05-19

Publications (2)

Publication Number Publication Date
WO2007030580A2 true WO2007030580A2 (fr) 2007-03-15
WO2007030580A3 WO2007030580A3 (fr) 2007-10-11

Family

ID=37836442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034796 Ceased WO2007030580A2 (fr) 2005-09-09 2006-09-08 Agents neuroprotecteurs

Country Status (1)

Country Link
WO (1) WO2007030580A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053430A1 (fr) * 2008-11-04 2010-05-14 Index Pharmaceuticals Ab Composés et procédés de réduction du recrutement et/ou de la migration de cellules polymorphonucléaires
EP2322178A3 (fr) * 2009-11-13 2012-01-04 Oregon Health & Science University Utilisation de TLR ligands pour le traitement d'une lésion excitotoxique, de l'ischémie et/ou de l'hypoxie
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2016183371A1 (fr) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés pour le traitement ou la prévention d'une lésion tissulaire ischémique
EP3325503A4 (fr) * 2015-07-17 2019-03-27 The University of Queensland Agents neuroprotecteurs dérivés de peptides de venin d'araignée
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US11359197B2 (en) 2018-01-12 2022-06-14 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US12241065B2 (en) 2018-01-12 2025-03-04 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255969A1 (en) * 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US10874725B2 (en) 2007-08-31 2020-12-29 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US10960019B2 (en) 2008-02-20 2021-03-30 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US8877724B2 (en) 2008-11-04 2014-11-04 Index Pharmaceuticals Ab Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
US10046006B2 (en) 2008-11-04 2018-08-14 Index Pharmaceuticals Ab Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
WO2010053430A1 (fr) * 2008-11-04 2010-05-14 Index Pharmaceuticals Ab Composés et procédés de réduction du recrutement et/ou de la migration de cellules polymorphonucléaires
EP2806028A2 (fr) 2008-11-04 2014-11-26 Index Pharmaceuticals AB Composés et procédés de réduction du recrutement et/ou de la migration de cellules polymorphonucléaires
EP2322178A3 (fr) * 2009-11-13 2012-01-04 Oregon Health & Science University Utilisation de TLR ligands pour le traitement d'une lésion excitotoxique, de l'ischémie et/ou de l'hypoxie
WO2016183371A1 (fr) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés pour le traitement ou la prévention d'une lésion tissulaire ischémique
US10485847B2 (en) 2015-07-17 2019-11-26 The University Of Queensland Neuroprotective agents derived from spider venom peptides
AU2016295423B2 (en) * 2015-07-17 2020-09-03 Monash University Neuroprotective agents derived from spider venom peptides
US10881712B2 (en) 2015-07-17 2021-01-05 The University Of Queensland Neuroprotective agents derived from spider venom peptides
EP3325503A4 (fr) * 2015-07-17 2019-03-27 The University of Queensland Agents neuroprotecteurs dérivés de peptides de venin d'araignée
US11359197B2 (en) 2018-01-12 2022-06-14 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US11447775B2 (en) 2018-01-12 2022-09-20 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US12180478B2 (en) 2018-01-12 2024-12-31 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US12241065B2 (en) 2018-01-12 2025-03-04 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Also Published As

Publication number Publication date
WO2007030580A3 (fr) 2007-10-11

Similar Documents

Publication Publication Date Title
US20110009445A1 (en) Neuroprotectants
US20100130425A1 (en) Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
US8853177B2 (en) Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
US20130123330A1 (en) Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases
TWI703214B (zh) 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用
KR102246814B1 (ko) 치료용 올리고뉴클레오타이드
WO2008154482A2 (fr) Compositions d'arnsi et procédés d'utilisation dans le traitement de maladies oculaires
TWI881004B (zh) 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合
CN107922947A (zh) 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂
JP2012136529A (ja) Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置
WO2007030580A2 (fr) Agents neuroprotecteurs
JP2017530948A (ja) 抗腫瘍組成物および方法
TW202320808A (zh) 用於治療多囊性腎病之方法及組合物
US20140005255A1 (en) Agonists Of Toll Like Receptor For Treating Cardiovasuclar Disease And Obesity
KR20230136593A (ko) 출혈 장애의 치료를 위한 조성물 및 방법
CN120957731A (zh) 用于治疗多囊肾病的修饰的寡核苷酸
KR20210078798A (ko) 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체를 유효성분으로 함유하는 치매 예방 또는 치료용 조성물
MX2013002722A (es) Acidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cancer.
KR20210088446A (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물
WO2016183370A1 (fr) Oligodésoxynucléotides immunosuppresseurs synthétiques pour la réduction d'une lésion tissulaire ischémique
KR20220026197A (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물
KR102630164B1 (ko) 펩티드 핵산 복합체를 유효성분으로 함유하는 비알콜성 지방간염 예방 또는 치료용 조성물
KR102320650B1 (ko) 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물
CN112654706B (zh) 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途
WO2016183371A1 (fr) Procédés pour le traitement ou la prévention d'une lésion tissulaire ischémique

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06814265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06814265

Country of ref document: EP

Kind code of ref document: A2